# US 2010/0303929 A1 · Compounds and methods for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0303929 A1
- Document ID: US20100303929A1
- Status: Published application
- Kind: A1
- Application number: 12/803,526
- Filed: 2010-06-29
- Published: 2010-12-02
- Earliest claimed: 2003-10-21
- Assignees: IGF Oncology, LLC
- Inventors: Hugh McTavish
- Web page: https://patentgrep.com/patent/US20100303929A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/08: of the prostate
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/00: Drugs for skeletal disorders
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 14/65: Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides a method of treating cancer involving administering an insulin-like growth factor-1 receptor (IGF-1 receptor) agonist and an anti-cancer chemotherapeutic agent. Also provided are compounds for treating cancer comprising an IGF-1-receptor ligand coupled to an anti-cancer chemotherapeutic agent. Also provided are compounds for treating cancer comprising an insulin-receptor ligand coupled to an anti-cancer chemotherapeutic agent.

## Claims

### Claim 1

A compound for treating cancer comprising:
an anti-cancer chemotherapeutic agent linked to
an insulin-like growth factor-1 (IGF-1) receptor ligand;
wherein the IGF-1 receptor ligand is a variant IGF-1 that has reduced binding affinity for soluble IGF-1 binding proteins compared to wild-type IGF-1
wherein the variant IGF-1 comprises the polypeptide structure A1-A2-A3-A4-LCG-A5-A6-LV-A7-AL-A8-A9-R1, wherein
A1 is G, V, or FV;
A2 is P or N;
A3 is E or Q;
A4 is T, H, or A;
A5 is A or S;
A6 is E or H;
A7 is D or E;
A8 is Q or Y;
A9 is F or L; and
R1 is SEQ ID NO:6;
provided the variant IGF-1 does not consist of SEQ ID NO:1;
wherein the variant IGF-1 does not comprise SEQ ID NO:11.

### Claim at position 2

2-5. (canceled)

### Claim 6 (depends on 1)

The compound of claim 1 wherein the chemotherapeutic agent is amsacrine, azacytidine, bleomycin, busulfan, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, cyclophosphamide, cytarabine, dactinomycin, daunorubicin, decarbazine, docetaxel, doxorubicin, epirubicin, estramustine, etoposide, floxuridine, fludarabine, fluorouracil, gemcitabine, hexamethylmelamine, idarubicin, ifosfamide, irinotecan, lomustine, mechlorethamine, melphalan, mercaptopurine, methotrexate, mitomycin C, mitotane, mitoxantrone, oxaliplatin, paclitaxel, pemetrexed, pentostatin, plicamycin, procarbazine, ralitrexed, semustine, streptozocin, temozolamide, teniposide, thioguanine, thiotepa, topotecan, trimitrexate, valrubicin, vincristine, vinblastine, vindestine, or vinorelbine.

### Claim 7 (depends on 1)

The compound of claim 1 wherein the chemotherapeutic agent is an anti-metabolite.

### Claim 8 (depends on 1)

The compound of claim 1 wherein the anti-cancer chemotherapeutic agent is linked to the IGF-1 receptor ligand by a linkage comprising an amide bond.

### Claim 9 (depends on 4)

The compound of claim 4 wherein the anti-cancer chemotherapeutic agent is linked to IGF-1 through an amino group of IGF-1.

### Claim 10 (depends on 7)

The compound of claim 7 wherein the anti-metabolite is methotrexate.

### Claim 11 (depends on 1)

The compound of claim 1 wherein the anti-cancer chemotherapeutic agent is doxorubicin.

### Claim at position 9

12-13. (canceled)

### Claim 14 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1.

### Claim at position 11

15-21. (canceled)
